• Journal of Chest Surgery
• /
• 제27권5호
• /
• pp.390-393
• /
• 1994

의료기술의 발달로 오늘날의 개심술은 대부분 성공적으로 시행되고 있지만 극히 일부분은 아직도 개심술후 심한 심실기능의 저하로 사망하는 겨우가 있다. 1960년대 중반 Spencer와 DeBakey에 의해 개심술후 심한 심실기능이 저하된 환자에게 심실보조장치를 이용하여 성공적으로 치험한 이후로 많은 발전을 거듭해 왔다. 저자들은 4개월 (6.5Kg)된 남아에서 개심술후 심한 저심박출증으로 인공심폐기의 제거를 못하여 좌심실 보조장치(Centrifugal Biopump)를 사용하여 성공적으로 치험하였기에 보고하는 바이다.

• Journal of Chest Surgery
• /
• 제39권11호
• /
• pp.854-857
• /
• 2006

환자는 8세 여자 환자로 확장성 심근병증을 진단 받은 환자이다. 환자는 심부전으로 인하여 양심실 순환보조를 15일간 시행하였다. 15일 중 후반기 7일은 급성 신부전증이 발생하여 지속적 정맥-정맥간 혈액투석을 시행하였다. 이후 뇌사상태의 A형 혈액형을 가진 심장 공여자에게서 심장을 이식받아 심장이식술을 시행하였다. 면역 억제제는 급성 신부전증을 고려하여 사용하였다. 신부전 상해는 2주간 지속되었고, 심장 이식술 후 약 14일 후 배뇨가 시작되었다. 환자는 수술 후 12일째에 시행한 우심실 조직검사에서 특별한 거부반응의 증거가 없었으며, 면역요법 후 수술 후 52일째에 특별한 문제 없이 퇴원하였다. 환자는 술 후 약 14개월간 조직검사에서 면역 거부반응 없이 외래 경과관찰 중이다.

• Journal of Chest Surgery
• /
• 제47권4호
• /
• pp.409-412
• /
• 2014

Percutaneous extracorporeal life support (P-ECLS) is a useful modality for the management of refractory cardiac or pulmonary failure. However, venoarterial P-ECLS may result in a complication of left ventricular distension. In this case report, we discuss a patient with drug-induced dilated cardiomyopathy managed with venoarterial P-ECLS and a left atrial vent catheter. The venoarterial P-ECLS was modified to a paracorporeal left ventricular assist device (LVAD) by removing the femoral venous cannula. After 28 days of hospitalization, the patient was successfully weaned from the paracorporeal LVAD and discharged home from the hospital.

• Journal of Chest Surgery
• /
• 제56권3호
• /
• pp.224-227
• /
• 2023

Median sternotomy is a standard surgical technique used for left ventricular assist device (LVAD) implantation. However, if sternotomy has a prohibitive surgical risk, LVAD implantation can be performed through only left thoracotomy. We managed a patient with end-stage heart failure who had recently undergone coronary artery bypass grafting (CABG) elsewhere. The patient also had a deep sternal wound infection and bacteremia. Because of refractory cardiogenic shock, we performed extracorporeal membrane oxygenation (ECMO). After multiple mediastinal washouts and omental flap placement, ECMO was converted to extracorporeal LVAD (from the left ventricular apex to the descending aorta) through a left thoracotomy. The extracorporeal LVAD was maintained for 18 days and replaced by the HeartMate 3 LVAD. The patient was discharged in good condition 115 days after CABG.

• 대한의용생체공학회:의공학회지
• /
• 제12권1호
• /
• pp.29-34
• /
• 1991

Ventricular assist device(VAD) has been clinically applied as a temporary circulatory sup- porting system in the patients with severe heart failure, but small sized VAD for infant is not available. The purpose of tilis paper is to introdIAce small sized VAD and presents the result of in vitro test. Sejong VAD is diaphragmatic type of pneumatic pump and stroke volume is 11cc. Cardiac outputs of the Sejong VAD were measured by overflow tank under variable conditions of driving parameters. The cardiac output was 1.3 1/min at the heart rate of 120 per minute, left atrial pressure of $15cmH_2O$, percent systole of 43%, driving pressure of 240 mmHg, vacuum pressure of -40 mmHg, and mean aortic pressure of 70 mmHg. No mechanical problem was developed during the continuous in vitro test for 3 months.

• Journal of Chest Surgery
• /
• 제53권6호
• /
• pp.368-374
• /
• 2020

Background: The extracorporeal ventricular assist device (e-VAD) system is designed for left ventricular support using a permanent life support console. This study aimed to determine the impact of temporary e-VAD implantation bridging on posttransplant outcomes. Methods: We reviewed the clinical records of 6 patients with the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) profile 1, awaiting heart transplantation, who were provided with temporary e-VAD from 2018 to 2019. The circuit comprised a single centrifugal pump without an oxygenator. The e-VAD inflow cannula was inserted into the apex of the left ventricle, and the outflow cannula was positioned in the ascending aorta. The median follow-up duration was 8.4±6.9 months. Results: After e-VAD implantation, lactate dehydrogenase levels significantly decreased, and Sequential Organ Failure Assessment scores significantly improved. Bedside rehabilitation was possible in 5 patients. After a mean e-VAD support duration of 14.5±17.3 days, all patients were successfully bridged to transplantation. After transplantation, 5 patients survived for at least 6 months. Conclusion: e-VAD may reverse end-organ dysfunction and improve outcomes in INTERMACS I heart transplant patients.

• 제어로봇시스템학회:학술대회논문집
• /
• 제어로봇시스템학회 1986년도 한국자동제어학술회의논문집; 한국과학기술대학, 충남; 17-18 Oct. 1986
• /
• pp.643-647
• /
• 1986

A new type of motor-driven Total Artificial Heart (TAH) system with rolling-ball mechanism has been developed. To test its performance as a Left Ventricular Assist Device (LVAD), LVAD is controlled to bypass blood for impaired heart triggered by the R-wave in ECG. Results of the test with a Mock Circulation System (MCS) and an animal experiment with a dog are also included. More powerful system using a brushless DC motor has been developed and its control scheme is represented.

• 한국정밀공학회지
• /
• 제17권11호
• /
• pp.5-16
• /
• 2000

• Journal of Chest Surgery
• /
• 제35권7호
• /
• pp.548-552
• /
• 2002

한국형 인공심장(AnyHeart)은 single moving actuator mechanism을 이용한 일체형 및 이식형 양심실 박동펌프이다. 저자 등은 양심 부전증에 의한 말기 심장병 환자에서 구난의료 차원으로 시도된 한국형 인공심장 (AnyHeart) 이식 1례를 경험하였기에 그 결과를 보고한다.

• Journal of Chest Surgery
• /
• 제57권3호
• /
• pp.315-318
• /
• 2024

The HeartWare Ventricular Assist Device (HVAD) was widely used for mechanical circulatory support in patients with end-stage heart failure. However, there have been reports of a critical issue with HVAD pumps failing to restart, or experiencing delays in restarting, after being stopped. This case report describes 2 instances of HVAD failure-to-restart during heart transplantation surgery and routine outpatient care. Despite multiple attempts to restart the pump using various controllers and extensions, the HVAD failed to restart, triggering a hazard alarm for pump stoppage. In one case, the patient survived after receiving a heart transplantation, while in the other, the patient died immediately following the controller exchange. These cases highlight the rare but life-threatening complication of HVAD failure-to-restart, underscoring the importance of awareness among clinicians, patients, and caregivers, and adherence to the manufacturer's guidelines and recommendations for HVAD management.